246 related articles for article (PubMed ID: 34407842)
1. SIRT1 regulates the phosphorylation and degradation of P27 by deacetylating CDK2 to promote T-cell acute lymphoblastic leukemia progression.
Wang F; Li Z; Zhou J; Wang G; Zhang W; Xu J; Liang A
J Exp Clin Cancer Res; 2021 Aug; 40(1):259. PubMed ID: 34407842
[TBL] [Abstract][Full Text] [Related]
2. Sirtuin 1 Activation Suppresses the Growth of T-lymphoblastic Leukemia Cells by Inhibiting NOTCH and NF-κB Pathways.
Okasha SM; Itoh M; Tohda S
Anticancer Res; 2020 Jun; 40(6):3155-3161. PubMed ID: 32487610
[TBL] [Abstract][Full Text] [Related]
3. The p27-Skp2 axis mediates glucocorticoid-induced cell cycle arrest in T-lymphoma cells.
Kullmann MK; Grubbauer C; Goetsch K; Jäkel H; Podmirseg SR; Trockenbacher A; Ploner C; Cato AC; Weiss C; Kofler R; Hengst L
Cell Cycle; 2013 Aug; 12(16):2625-35. PubMed ID: 23907123
[TBL] [Abstract][Full Text] [Related]
4. SIRT1-mediated downregulation of p27Kip1 is essential for overcoming contact inhibition of Kaposi's sarcoma-associated herpesvirus transformed cells.
He M; Yuan H; Tan B; Bai R; Kim HS; Bae S; Che L; Kim JS; Gao SJ
Oncotarget; 2016 Nov; 7(46):75698-75711. PubMed ID: 27708228
[TBL] [Abstract][Full Text] [Related]
5. p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.
Zhao H; Lu Z; Bauzon F; Fu H; Cui J; Locker J; Zhu L
Oncogene; 2017 Jan; 36(1):60-70. PubMed ID: 27181203
[TBL] [Abstract][Full Text] [Related]
6. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
Sanda T; Li X; Gutierrez A; Ahn Y; Neuberg DS; O'Neil J; Strack PR; Winter CG; Winter SS; Larson RS; von Boehmer H; Look AT
Blood; 2010 Mar; 115(9):1735-45. PubMed ID: 20007543
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein promotes acute kidney injury via Smad3-dependent inhibition of CDK2/cyclin E.
Lai W; Tang Y; Huang XR; Ming-Kuen Tang P; Xu A; Szalai AJ; Lou TQ; Lan HY
Kidney Int; 2016 Sep; 90(3):610-26. PubMed ID: 27470679
[TBL] [Abstract][Full Text] [Related]
8. Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27.
García-Gutiérrez L; Bretones G; Molina E; Arechaga I; Symonds C; Acosta JC; Blanco R; Fernández A; Alonso L; Sicinski P; Barbacid M; Santamaría D; León J
Sci Rep; 2019 Dec; 9(1):18693. PubMed ID: 31822694
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
[TBL] [Abstract][Full Text] [Related]
10. SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27.
Zhu L; Chiao CY; Enzer KG; Stankiewicz AJ; Faller DV; Dai Y
Mol Cancer Res; 2015 Jan; 13(1):41-9. PubMed ID: 25143434
[TBL] [Abstract][Full Text] [Related]
11. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
[TBL] [Abstract][Full Text] [Related]
12. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association.
Mao B; Zhao G; Lv X; Chen HZ; Xue Z; Yang B; Liu DP; Liang CC
Int J Biochem Cell Biol; 2011 Nov; 43(11):1573-81. PubMed ID: 21807113
[TBL] [Abstract][Full Text] [Related]
13. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.
Matsushita K; Kitamura K; Rahmutulla B; Tanaka N; Ishige T; Satoh M; Hoshino T; Miyagi S; Mori T; Itoga S; Shimada H; Tomonaga T; Kito M; Nakajima-Takagi Y; Kubo S; Nakaseko C; Hatano M; Miki T; Matsuo M; Fukuyo M; Kaneda A; Iwama A; Nomura F
Oncotarget; 2015 Mar; 6(7):5102-17. PubMed ID: 25671302
[TBL] [Abstract][Full Text] [Related]
14. A Therapeutically Targetable NOTCH1-SIRT1-KAT7 Axis in T-cell Leukemia.
Lancho O; Singh A; da Silva-Diz V; Aleksandrova M; Khatun J; Tottone L; Nunes PR; Luo S; Zhao C; Zheng H; Chiles E; Zuo Z; Rocha PP; Su X; Khiabanian H; Herranz D
Blood Cancer Discov; 2023 Jan; 4(1):12-33. PubMed ID: 36322781
[TBL] [Abstract][Full Text] [Related]
15. p27 is regulated independently of Skp2 in the absence of Cdk2.
Kotoshiba S; Gopinathan L; Pfeiffenberger E; Rahim A; Vardy LA; Nakayama K; Nakayama KI; Kaldis P
Biochim Biophys Acta; 2014 Feb; 1843(2):436-45. PubMed ID: 24269842
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of the Ink4a-Arf (Cdkn2a) tumor suppressor locus in the initiation and progression of Notch1-driven T cell acute lymphoblastic leukemia.
Volanakis EJ; Boothby MR; Sherr CJ
Exp Hematol; 2013 Apr; 41(4):377-86. PubMed ID: 23178376
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitination of p27Kip1 requires physical interaction with cyclin E and probable phosphate recognition by SKP2.
Ungermannova D; Gao Y; Liu X
J Biol Chem; 2005 Aug; 280(34):30301-9. PubMed ID: 15980415
[TBL] [Abstract][Full Text] [Related]
18. PI 3-kinase/Rac1 and ERK1/2 regulate FGF-2-mediated cell proliferation through phosphorylation of p27 at Ser10 by KIS and at Thr187 by Cdc25A/Cdk2.
Lee JG; Kay EP
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):417-26. PubMed ID: 20811053
[TBL] [Abstract][Full Text] [Related]
19. SKP2 overexpression is associated with increased serine 10 phosphorylation of p27 (pSer10p27) in triple-negative breast cancer.
Fagan-Solis KD; Pentecost BT; Gozgit JM; Bentley BA; Marconi SM; Otis CN; Anderton DL; Schneider SS; Arcaro KF
J Cell Physiol; 2014 Sep; 229(9):1160-9. PubMed ID: 24443386
[TBL] [Abstract][Full Text] [Related]
20. SIRT1 inhibition impairs non-homologous end joining DNA damage repair by increasing Ku70 acetylation in chronic myeloid leukemia cells.
Zhang W; Wu H; Yang M; Ye S; Li L; Zhang H; Hu J; Wang X; Xu J; Liang A
Oncotarget; 2016 Mar; 7(12):13538-50. PubMed ID: 26646449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
